Sterile, single use, eyelid weight implant segments, used to treat Lagophthalmos to weigh down the upper eye lid to aid closure, used in combinations to achieve optimum result for each patient. The devices are made of 90% platinum 10% iridium, an industry standard alloy utilized for eyelid implants. The segments are rectangular in shape, contoured to the shape of the eye, with suture holes for both linking segments together in a chain and securing segments into position. Two sizes of segments are provided, with total weight customized for patient need by surgeon selection of segment combinations. The min/max combination range is from total 0.4g to total 2.0g. They achieve their intended purpose through gravity, weighing down the upper eyelid.

AI/ML Overview

The provided document is a 510(k) summary for the Altomed Malhotra Platinum Segments, an eyelid implant. It focuses on demonstrating substantial equivalence to a predicate device (Heinz Kurz Platinum Implants) rather than proving specific performance metrics against pre-defined acceptance criteria for a novel device.

Therefore, the document does not contain the information requested regarding acceptance criteria and a study proving the device meets them in the context of typical AI/ML medical device performance studies (sensitivity, specificity, reader studies, etc.). Instead, it focuses on material equivalence, biocompatibility, sterility, shelf life, and MRI compatibility.

Here's why the requested information cannot be extracted from this document:

Type of Device: This device is a passive implant that treats lagophthalmos through gravity (weighing down the eyelid). It is not an AI/ML diagnostic or prognostic device that would have performance metrics like sensitivity, specificity, or require reader studies for its primary function.
Regulatory Pathway: A 510(k) submission aims to show "substantial equivalence" to a legally marketed predicate device. This often involves demonstrating similar technological characteristics, intended use, and safety/performance profiles, rather than proving novel performance against a predefined set of acceptance criteria in a clinical study of AI performance.
"Performance Data" Section: The "Performance Data" section (Section 7) describes testing for biocompatibility, sterility/shelf life, and MR compatibility. These are safety and engineering performance tests relevant to an implantable device, not diagnostic accuracy or clinical effectiveness involving human-AI interaction or AI-alone performance.

Therefore, I cannot populate the table or answer the specific questions related to AI/ML device performance studies based on the provided text.

If this were an AI/ML device submission, the "Performance Data" section would typically contain information such as:

Acceptance Criteria Table: Define thresholds for metrics like sensitivity, specificity, AUC, etc.
Study Design: Details on the prospective/retrospective nature, data provenance, sample size of the test set, and how ground truth was established (e.g., expert consensus with adjudication, pathology, clinical outcomes).
Reader Studies (if applicable): Number and qualifications of readers, study design (e.g., MRMC), and results comparing human performance with and without AI assistance.
Standalone Performance: AI algorithm performance without human intervention.
Training Set Details: Sample size and ground truth establishment for the training data.

Summary

{0}------------------------------------------------

Public Health Service

Image /page/0/Picture/2 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features the department's name encircling a symbol. The symbol consists of a stylized caduceus, which is a traditional symbol of medicine, with three figures representing health, services, and human needs.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

June 6, 2017

Altomed Limited Stuart March 2 Witney Way Boldon Business Park Tyne & Wear NE35 9PE England

Re: K170591

Trade/Device Name: Altomed Malhotra Platinum Segments Regulation Number: 21 CFR 886.5700 Regulation Name: Eyelid weight Regulatory Class: Class II Product Code: MML Dated: March 17, 2017 Received: March 20, 2017

Dear Stuart March:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

{1}------------------------------------------------

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely.

Denise L. Hampton -S

for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

510(k) Number (if known)

Device Name

Altomed Malhotra Platinum Segments

Indications for Use (Describe)

Malhotra Platinum Segments are eyelid implants designed for the gravity-assisted treatment of lagophthalmos.

Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the
time to review instructions, search existing data sources, gather and maintain the data needed and complete
and review the collection of information. Send comments regarding this burden estimate or any other aspect
of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services

Food and Drug Administration

Office of Chief Information Officer

Paperwork Reduction Act (PRA) Staff

PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summary, K170591:

1. Submitter/510(k) Owner:

Altomed Limited 2 Witney Way, Boldon Tyne and Wear, England, NE35 9PE Contact Person: Stuart March Tel: (0) 191 519 0111 Fax: (0) 191 519 0283 Date prepared: June 1, 2017

2. Device:

Device Proprietary Name: Malhotra Platinum Segments Device Common Name: Implantable Eyelid Weight Classification: Class II Classification Name: Implantable Eyelid Weight Product Code: MML

3. Predicate Device: K011115, Heinz Kurz Platinum Implants

4. Device Description:

5. Indications For Use:

Malhotra Platinum Segments are evelid implants designed for the gravity-assisted treatment of laqophthalmos.

6. Technological Characteristics and Substantial Equivalence:

The Malhotra Platinum Segments have the same intended use and similar technical characteristics to the predicate device. Both devices are intended for treatment of lagophthalmos, assisting eyelid closure by the addition of weights implanted into the upper eyelid. Both devices are made from a 90%/10% platinum/iridium alloy. They are similar in shape and size, customizable by the surgeon according to patient need and fixed into place with sutures. While the predicate device comes in a range of sizes, the Malhotra Platinum Segments are used in customized combinations to achieve the desired size. Both are provided sterile. The Malhotra Platinum Segments are sterilized with ethylene oxide. EO residuals have been determined to be well below established limits for implanted medical devices; therefore, this difference in technological characteristic raises no new issue of safety.

{4}------------------------------------------------

Characteristics	Subject Device	Predicate Device	Comparison
Trade Name	Malhotra Platinum Segments	Heinz Kurz PlatinumImplants
510(k) Number	TBD	K011115
FDA ProductCode	MML	MML	Equivalent
Indications foruse	Gravity-assisted treatment oflagophthalmos.	Treatment of lagophthalmosby optimization of lid closurethrough addition of weight toupper lid.	Equivalent meaning
Anatomical site,exposure duration	Eyelid implant, permanent	Eyelid implant, permanent	Equivalent
Principle ofoperation	Implants provide theadditional weight needed to close theupper eyelid when the orbitalmusculature is compromised byfacial paralysis.	Implants provide theadditional weight needed toclose the upper eyelid whenthe orbital musculature iscompromised by facialparalysis.	Equivalent
Technique forapplication	Surgeon determines appropriateweight. Segment implants aresurgically inserted and suturedtogether and into place. Surgicallyreversible.	Surgeon determinesappropriate weight. Implantsare surgically inserted,sutured into place.Surgically reversible.	Equivalent
Sizes/description	Rectangular, shaped to fit curvatureof the eyeball, comes in 2 sizes.Designed to be used in customcombinations to achieve desiredweight, with max of 2.0g:A7080: 6.00mm x 2.30mm x1.00mm; 0.2g; curved, 3 suture holes0.95mm in diameterA7082: 6.00mm x 4.00mm x1.00mm; 0.4g; curved, 4 suture holes0.95mm in diameter	Rectangular, shaped to fitcurvature of the eyeball.Sizes vary from:0.6 to 2.2g in 0.2gincrements;15mm x 5mm to20mm x 5.2mm,with 4 suture holes.	Same basic shape andweight range covered.
Materials	90% Platinum, 10% Iridium	90% Platinum, 10% Iridium	Equivalent
MRI Compatibility	MR Conditional	MR Conditional	Equivalent
Sterility	Ethylene Oxide Sterilized, SAL 10-6	Gamma Sterilized, SAL 10-6	Same Sterility AssuranceLevel; low EO residualsraise no new questions ofsafety.

7. Performance Data:

a) Biompatibility Testing:

Biocompatibility evaluation conducted on the Malhotra Platinum Segments shows the suitability of materials permanently exposed to tissue. Both implant materials used in the manufacturing process were reviewed. Standards relevant to the evaluation are BS EN ISO 10993-1:2009, Biological evaluation of medical devices Part 1 Evaluation and testing, and BS EN ISO 10993-18:2009, Biological evaluation of medical devices Part 18, Chemical characterization of materials.

{5}------------------------------------------------

The material used in this medical device is a clinically established material for use in invasive applications, and is the identical material used in the predicate device, which has been on the market since 2001: platinum/iridium alloy, 90%/10%.

BS EN ISO 10993-18:2009 identifies that a documented qualitative description of the finished device, including additives and processing residues for each material used, is required as part of the determination of material equivalence. Compositional analysis of the Malhotra Platinum Segments has been performed using x-ray fluorescence and induction coupled plasma techniques. Safety information for the processing materials has been obtained and evaluated.

Ethylene Oxide does not alter the biocompatibility of the Malhotra Platinum Segments as they are made of metal, are very small, do not have grooves or cavities, and therefore not highly retentive of EO residuals. EO Residuals for the Platinum Segments have been determined to be well within acceptable levels as specified in ISO 10993-7.

Paragraph 6.1 (material characterization) of BS EN ISO 10993-1:2009 states that if the combination of all materials, chemicals and processes has an established history of safe use in the intended application, then further characterization and biological evaluation might not be necessary. The material used in this medical device is a clinically established material for use in invasive applications, and is identical to the material used in the predicate device, having a toxicological safety no worse than that of the predicate.

b) Sterility and Shelf Life:

Sterilization validation was completed according to ISO 11135-1:2007. Sterilization of health products -Ethylene Oxide – Requirement, validation and routine control of a sterilization process for medical devices. The Half-Cycle Method test results demonstrated EO sterilization to a Sterility Assurance Level of 10 °. Validation is repeated yearly.

A five-year shelf life was validated using real-time aging, shipping, visual inspection, dye leak tesing, and seal strength testing. Test results demonstrated that package integrity and product sterility are maintained over the stated five-year shelf life. Tests were completed according to:

. Visual Seal Integrity Inspection (ASTM F1886 / F1886M-09, 2013)
. Package burst strength (ASTM F1140/F1140M-13)
. Package Dye Leak Test (ASTM F1929-12)

c) MR Compatibility:

MRI Compatibility testing according to recognized standards was undertaken to determine magnetic field interactions, heating, and image artifacts for the Malhotra Platinum Segments to support the claim of "MR Conditional." Worst-case product configuration and positioning for MRI-related heating was determined. Testing demonstrated that the implants are conditionally safe when exposed to a magnetic field of 3-Tesla or less.

i. MRI Related force
For the assessment of translational attraction, a deflection angle test was conducted. A 3-Tesla (GE Excite) active-shielded, MRI scanner was used for the assessments of magnetic field interactions. The Malhotra Platinum Segment was attached to a special non-metallic, test apparatus to measure the deflection angle in the MR system. The finding for translational attraction for the Malhotra Platinum Segment was 2-degrees.

{6}------------------------------------------------

Torque testing was conducted with the Malhotra Platinum Segment on a test apparatus positioned in the center of the MR system. The Malhotra Platinum Segment was directly observed for possible movement with respect to alignment or rotation relative to the static magnetic field of the 3-Tesla MR system. The following qualitative scale of torque was applied to the results: 0 (no torque) up to +4 (very strong torque). The qualitatively measured torque at 3-Tesla for the Malhotra Platinum Segment was 0, no torque.

ii. MRI Related Heating
MRI-related heating evaluation at 1.5-Tesla/64-MHz in worst-case positioning indicated that the greatest amount of heating that occurred in association with these specific conditions was equal to or less than 2.0°C. The result for testing at 3-Tesla/128-MHz indicated that the greatest amount of heating was equal to or less than 1.5°C
iii. MRI Related artifact
MRI Related artifact testing for both echo pulse and echo spin sequences was conducted. The gradient echo pulse sequence produced larger artifacts than the T1-weighted, spin echo pulse sequence for the device. The maximum artifact size (i.e., as seen on the gradient echo pulse sequence) extends approximately 10-mm relative to the size and shape of the Malhotra Platinum Segment.

8. Conclusion:

The Malhotra Platinum Segment device is substantially equivalent to the predicate devices based on having the same intended use and similar technological characteristics. Minor differences in technological characteristics, size configuration and sterilization method, do not raise new issues of safety or efficacy. Performance data demonstrate sterility, shelf life, biocompatibility in a magnetic resonance environment.

Regulation Number and Section

§ 886.5700 Eyelid weight.

(a)
Identification. An eyelid weight is a prescription device made of gold, tantalum, platinum, iridium, or surgical grade stainless steel that is rectangular in shape and contoured to the shape of the eye. The device is intended for the gravity assisted treatment of lagophthalmos (incomplete eyelid closure).(1) The external eyelid weight is adhered to the outer skin of the upper eyelid.
(2) The implantable eyelid weight is implanted into the upper eyelid.
(b)
Classification. (1) Class II (special controls) for the external eyelid weight. The external eyelid weight is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9. The special controls for the external eyelid weight are:(i) Testing demonstrating the biocompatibility of the device; and
(ii) Labeling must include the following information:
(A) Specific instructions regarding the proper placement, sizing, and removal of the device; and
(B) A warning stating that the patient should be instructed to remove the device prior to entering a magnetic resonance environment.
(2) Class II (special controls) for the implantable eyelid weight. The special controls for the implantable eyelid weight are:
(i) Testing demonstrating the biocompatibility of the device;
(ii) Testing demonstrating the sterility and shelf life of the device;
(iii) Nonclinical testing evaluating the compatibility of the device in a magnetic resonance environment.
(iv) Patient labeling to convey information regarding the safety and compatibility of the device in a magnetic resonance environment, the conditions under which a patient with the device can be safely scanned, and a mechanism for a healthcare provider to obtain detailed information about magnetic resonance safety and compatibility if needed.